Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial.

JAMA ophthalmology(2023)

引用 0|浏览5
暂无评分
摘要
ClinicalTrials.gov Identifier: NCT04450329.
更多
查看译文
关键词
aflibercept biosimilar sb15,age-related
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要